Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans.


1. PM103 is an intravenous formulation of clopidogrel being developed as an alternative to oral clopidogrel to provide for dosing flexibility in the emergent clinical setting. The present first-in-human study assessed the pharmacokinetic and pharmacodynamic effects of PM103 and its safety in 144 healthy human subjects. 2. The present was a randomized open… (More)
DOI: 10.1111/j.1440-1681.2011.05616.x


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics